Biotec Pharmacon receives promising interim results from animal study
(Thomson Reuters ONE) -
Tromsø, 21 January 2011
Biotec Pharmacon ASA has received an interim data report from the second animal
study in diabetic mice. The results confirm the finding from the first study
showing that a 2% aqueous solution of SBG has good wound healing capability. An
important goal with the second study was to investigate different concentrations
of SBG, and SBG in combination with an additional gel agent. Preliminary
stability data has indicated that a mixed formulation would have increased
stability as compared to a pure 2% aqueous solution of SBG. Also, different
commercial hydrogels typically used in wound healing was included.
The results showed that SBG successfully can be mixed with different gel agents,
and results also indicate that such mix improves the wound healing capability of
the product. The best results were obtained with a combination of 2% SBG and
carboxymethylcellulose (CMC), the latter being used in several of the commercial
wound treatment hydrogels on the market, like Intrasite from Smith & Nephew and
in the wound healing drug Regranex. This combination product of SBG and CMC
induced statistically significant improved wound healing from day 12 and onwards
throughout the study (day 24) only paralleled by the positive control. The
results also confirm that such a SBG based product performs better than the
other commonly used hydrogels containing CMC tested and also methylcellulose
that was the placebo of the clinical studies.
As earlier reported, it was observed that a pure 2% aqueous solution of SBG when
stored in aluminum tubes or polyethylene ampoules, were very sensitive to
accelerated storage conditions as seen by early fragmentation of the gel. These
two container types were accordingly chosen for the ongoing stability program to
secure rapid progress in testing the new formulations. Preliminary data from the
accelerated stability studies have so far indicated that the stability of SBG
can be significantly improved. Either by increasing the concentration of SBG
alone above 2% in water, resulting in a more solid gel, or by mixing SBG with an
additional gel agent like CMC.
"We are very pleased with these results as they are important in our efforts to
develop a robust and commercially attractive product for topical wound healing",
says Svein Lien, CEO of Biotec Pharmacon.
Please find enclosed the complete update including the graphs from the study.
For further information, please contact:
Svein W. F. Lien - CEO +47 92289323
This information is subject of the disclosure requirements acc. to 22§5-12 vphl
(Norwegian Securities Trading Act)
About Biotec Pharmacon:
Biotec Pharmacon is a biopharmaceutical company that develops and manufactures
new immunomodulatory products and cold adapted marine enzymes. The company
focuses on new and effective solutions within wound care, cancer therapies and
other immune related disease areas, and aspires to become a leading supplier of
novel enzymes for diagnostics and genetic research.
BIOTEC 2nd update SBG results:
http://hugin.info/136141/R/1481476/416832.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biotec Pharmacon ASA via Thomson Reuters ONE
[HUG#1481476]
Unternehmensinformation / Kurzprofil:
Datum: 21.01.2011 - 16:53 Uhr
Sprache: Deutsch
News-ID 50640
Anzahl Zeichen: 3995
contact information:
Town:
Tromsø
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biotec Pharmacon receives promising interim results from animal study"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
